Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Vicky Makker
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama
Birmingham, Alabama, United States
- Pacific Cancer Specialists
Anaheim, California, United States
- Valkyrie Clinical Trials
Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian
Newport Beach, California, United States
- Community Health Network, Inc.
Indianapolis, Indiana, United States
- Mayo Clinic - Rochester
Rochester, Minnesota, United States
- New Jersey Cancer Care, Pa
Belleville, New Jersey, United States
- Englewood Health
Englewood, New Jersey, United States
- Northwell Health
Lake Success, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- East Carolina University
Greenville, North Carolina, United States
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, United States
- Avera Cancer Institute
Sioux Falls, South Dakota, United States
- Baptist Hospitals of Southeast Texas
Beaumont, Texas, United States
- Oncology Consultants, Pa
Houston, Texas, United States
- Lumi Research
Kingwood, Texas, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Apr 2022
- Primary completion
- 30 Apr 2025
- Completion
- 30 Apr 2025
- Last update posted
- 30 Apr 2026
- Registered enrollment
- 34
- Registry id
- NCT05300048
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.